Hemodialysis Fistula Thrombosis, Platelet Activation
Conditions
Brief summary
In the case of cardiovascular diseases such as coronary artery disease, cerebrovascular disease, and peripheral arterial disease, there are many studies that the use of antiplatelet agents is very helpful in improving the vascular patency rate, but there are not many studies on the use of antiplatelet agents in the dialysis approach. The basis for use is insufficient. There is a lack of research on whether maintaining a state in which platelet activation is suppressed is helpful in improving dialysis access patency. Therefore, we conducted this study to determine whether the degree of platelet activation affects the patency of vascular access.
Interventions
BIOLOGICALplatelet activation factors
platelet activation factors of subject blood
Sponsors
Korea University Anam Hospital
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients 19 years of age or older who are undergoing hemodialysis during renal replacement therapy * Patients undergoing arteriovenous fistula formation and hemodialysis to the affected area * Patients who have the ability and willingness to consent to participate in the clinical study, have signed the consent form in accordance with the appropriate procedures, and can visit and participate in the clinical study as planned
Exclusion criteria
* Patients who failed to start hemodialysis with an arteriovenous fistula within 3 months * Patients who have had stent implantation or surgery during the study period due to cardiovascular disease * Patients with severe hepatic impairment * Patients with coagulopathy and liver disease associated with clinically significant bleeding risk * Patients with clinically significant bleeding or bleeding risk * Patients who underwent artificial heart valve replacement requiring anticoagulant administration * Patients with pulmonary embolism who are hemodynamically unstable or require thrombolysis or pulmonary embolization. * Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Vascular access primary patency | 1 month | Time from vascular access creation until hemodialysis related procedure |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Vascular access secondary patency | 1 month | Time from vascular access creation until hemodialysis failure |
Countries
South Korea
Outcome results
None listed